KT-294 / Kymera Therap - LARVOL DELTA

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) - "The Company nominated a new TYK2 development candidate, KT-295, a potent, selective, once daily oral degrader, and has prioritized this compound for clinical evaluation. KT-295 has picomolar potency and is highly selective for TYK2, while also demonstrating greater in vivo activity in preclinical animal models compared to KT-294, the Company’s previously identified TYK2 degrader; Kymera intends to advance KT-295 into Phase 1 clinical testing in the first half of 2025, which is consistent with prior program guidance. The Company expects to report Phase 1 data later that year."

New molecule • New P1 trial • P1 data • Preclinical • Immunology • Inflammation • Inflammatory Bowel Disease • Psoriasis

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting (GlobeNewswire) - "Based on the results generated to date, Kymera intends to initiate Phase 1 testing for KT-621 and KT-294 in the in the second half of 2024 and the first half of 2025, respectively. Data from both Phase 1 trials are expected to be reported in 2025....The findings presented today demonstrate that in preclinical studies, KT-621...was exquisitely selective for STAT6 over other STATs and fully blocked IL-4/IL-13 functions in key human TH2 cellular assays with picomolar potency that was superior to dupilumab....Additionally, in preclinical studies, KT-294...demonstrated picomolar degradation potency and potent inhibition of the IL-23, IL-12 and Type I IFN pathways, showing its potential to recapitulate the biology of human TYK2 loss-of-function profile."

New P1 trial • P1 data • Preclinical • Atopic Dermatitis • Immunology

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (Yahoo Finance) - "This profile has the potential to circumvent the limitations of both selective and non-selective TYK2 small molecule inhibitors, providing a best-in-class opportunity in several indications including inflammatory bowel disease, lupus and psoriasis....The Company plans to share additional preclinical data at upcoming medical meetings, expects to initiate a Phase 1 clinical trial in the first half of 2025 and report the Phase 1 results in 2025."

New P1 trial • P1 data • Preclinical • Inflammatory Arthritis • Lupus • Psoriasis